The results of this study provide conclusive evidence that loss of DLC1, combined with an oncogenic stimulus, promotes HCC in vivo and that this oncogenic process is associated with activation of RhoA, which is a key consequence of loss of DLC1 tumor suppressor activity (53,54). This evidence concerns the gene RHOA and neoplasm.